Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study
The aims were to describe efficacy and tolerability of regimens containing dolutegravir (DTG) in advanced ARTnaïve
people living with HIV (PLHIV) from the clinical practice.
The frequency of Immune Reconstitution Inflammatory Syndrome (IRIS), the estimated time of discontinuation
of the first ART regimen and the time to reach virological suppression in a multicenter cohort of
AIDS-presenters or late-presenters with CD4<350/μL were assessed.
We included 272 PLHIV: 120 (44%) AIDS-presenters and 152 (56%) late-presenters. The most frequent AIDSdefining